Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes
| Status: | Terminated |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | January 2014 |
| End Date: | December 2015 |
Purpose: The purpose of this study is to see whether a text-message reminder system will
increase the number of women who complete their diabetes screening after delivery.
Study Design: Prospective randomized control trial
Hypothesis: Gestational diabetics will be significantly more likely to follow up with their
postpartum screening for diabetes if they receive text-message reminders to set up their lab
appointment compared to those who receive usual care.
increase the number of women who complete their diabetes screening after delivery.
Study Design: Prospective randomized control trial
Hypothesis: Gestational diabetics will be significantly more likely to follow up with their
postpartum screening for diabetes if they receive text-message reminders to set up their lab
appointment compared to those who receive usual care.
Eligible participants will be recruited after delivery while on the postpartum ward.
Recruitment will be conducted by the PI or a member of the study team. After informed
consent is obtained, the patients will be randomized into one of two study groups: the
intervention group or the control group. Women in the intervention group will receive a test
text-message reminder at the time of enrollment. They will then receive a text-reminder to
schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at
3 months and 6 months if they have not completed their testing. Women in the control group
will only receive the test text-message reminder. The PI or member of the study team
obtaining the informed consent will verify the participant has received the text-message
prior to completing enrollment. A computer-generated randomization list will be generated
according to intervention vs. control group. Simple randomization will be used for the
purposes of this study. 316 participants will be recruited based on the sample size
calculations already performed. One group of 316 randomized opaque envelopes will be
prepared. These sealed envelopes will be stored in a secured designated area at Tampa
General Hospital. Once a patient has agreed to participate and is consented an envelope will
be selected from the next sequentially numbered envelope and the number on the envelope will
be recorded on their study sheet. Enrollment will continue until 316 participants have been
recruited.
Recruitment will be conducted by the PI or a member of the study team. After informed
consent is obtained, the patients will be randomized into one of two study groups: the
intervention group or the control group. Women in the intervention group will receive a test
text-message reminder at the time of enrollment. They will then receive a text-reminder to
schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at
3 months and 6 months if they have not completed their testing. Women in the control group
will only receive the test text-message reminder. The PI or member of the study team
obtaining the informed consent will verify the participant has received the text-message
prior to completing enrollment. A computer-generated randomization list will be generated
according to intervention vs. control group. Simple randomization will be used for the
purposes of this study. 316 participants will be recruited based on the sample size
calculations already performed. One group of 316 randomized opaque envelopes will be
prepared. These sealed envelopes will be stored in a secured designated area at Tampa
General Hospital. Once a patient has agreed to participate and is consented an envelope will
be selected from the next sequentially numbered envelope and the number on the envelope will
be recorded on their study sheet. Enrollment will continue until 316 participants have been
recruited.
Inclusion Criteria:
- Women diagnosed with gestational diabetes (GDM) based on a 100-g, 3-hour glucose
tolerance test with 2 or more abnormal values according to the Carpenter-Coustan
criteria OR Women with a 50-g, 1-hour loading test >200mg/dl.
- Diagnosed with GDM at least at 24 weeks gestation or later
- Access to a personal mobile phone with text-messaging capabilities.
- Age 18 or greater
- Able to provide written and informed consent in English or Spanish language
Exclusion Criteria:
- Women that were ever diagnosed with diabetes outside of pregnancy.
We found this trial at
1
site
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
Click here to add this to my saved trials
